Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue.
Serum HER-2/neu (c-erbB-2) levels in patients with gastric cancer were evaluated by an enzyme-linked immunosorbent assay and tissue levels of HER-2/neu in the same cohort were determined by immunohistochemistry. Nine (16%) of 57 gastric carcinomas had an overexpression of HER-2/neu detected immunohistochemically. Of these 9 patients, 6 had elevated serum HER-2/neu levels, while 45 of 48 tissue samples with negative staining exhibited normal serum HER-2/neu levels. These results indicated that overall accuracy, positive predictive value, and negative predictive values of their serum measurements were 89, 67 and 94%, respectively. Serum levels of HER-2/neu were correlated with tissue overexpression of HER-2/neu in patients with gastric cancer.
Kono
K
K
First Department of Surgery, Yamanashi Medical University, Yamanashi, Japan. kojikono@res.yamanashi-med.ac.jp
Naganuma
H
H
Sekikawa
T
T
Amemiya
H
H
Takahashi
A
A
Iizuka
H
H
Matsumoto
Y
Y
D000230:Adenocarcinoma / Q000097:blood* / Q000737:chemistry* / Q000175:diagnosis / Q000473:pathology; D000368:Aged; D018279:Carcinoma, Signet Ring Cell / Q000097:blood / Q000737:chemistry / Q000175:diagnosis / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000097:blood*; D013223:Statistics as Topic; D013274:Stomach Neoplasms / Q000097:blood* / Q000737:chemistry* / Q000175:diagnosis / Q000473:pathology; D015854:Up-Regulation
D018719:Erb-b2 Receptor Tyrosine Kinases